MX2024012230A - Tratamientos conjuntos que comprenden gdc-6036 y gdc-0077 para el tratamiento de cancer - Google Patents
Tratamientos conjuntos que comprenden gdc-6036 y gdc-0077 para el tratamiento de cancerInfo
- Publication number
- MX2024012230A MX2024012230A MX2024012230A MX2024012230A MX2024012230A MX 2024012230 A MX2024012230 A MX 2024012230A MX 2024012230 A MX2024012230 A MX 2024012230A MX 2024012230 A MX2024012230 A MX 2024012230A MX 2024012230 A MX2024012230 A MX 2024012230A
- Authority
- MX
- Mexico
- Prior art keywords
- gdc
- cancer
- treatment
- treatments including
- joint treatments
- Prior art date
Links
- SGEUNORSOZVTOL-CABZTGNLSA-N (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(OC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F SGEUNORSOZVTOL-CABZTGNLSA-N 0.000 title abstract 2
- ZRBPIAWWRPFDPY-IRXDYDNUSA-N 1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound NC1=NC(=C(C(=C1)C)C(F)(F)F)C1=C(Cl)C=C2C(N3CCN(C[C@@H]3C)C(=O)C=C)=NC(=NC2=C1F)OC[C@H]1N(C)CCC1 ZRBPIAWWRPFDPY-IRXDYDNUSA-N 0.000 title abstract 2
- 229940126265 GDC-6036 Drugs 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 229940071122 inavolisib Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328149P | 2022-04-06 | 2022-04-06 | |
| PCT/US2023/017455 WO2023196329A1 (en) | 2022-04-06 | 2023-04-04 | Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012230A true MX2024012230A (es) | 2024-11-08 |
Family
ID=86286527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012230A MX2024012230A (es) | 2022-04-06 | 2024-10-03 | Tratamientos conjuntos que comprenden gdc-6036 y gdc-0077 para el tratamiento de cancer |
Country Status (13)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250000802A1 (en) * | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111909173B (zh) | 2015-07-02 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| KR20210035211A (ko) * | 2018-07-23 | 2021-03-31 | 에프. 호프만-라 로슈 아게 | Pi3k 저해제인 gdc-0077로 암을 치료하는 방법 |
| WO2020097537A2 (en) | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| TWI829003B (zh) | 2020-08-12 | 2024-01-11 | 美商建南德克公司 | 喹唑啉化合物之合成 |
| EP4243827A1 (en) | 2020-11-13 | 2023-09-20 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer |
| KR102975432B1 (ko) | 2020-11-13 | 2026-06-10 | 제넨테크, 인크. | 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물 |
| TWI895563B (zh) | 2020-12-08 | 2025-09-01 | 美商建南德克公司 | 用於治療實性瘤之包含ｋｒａｓｇ１２ｃ抑制劑及ｅｇｆｒ抑制劑之組成物及方法 |
| AR128449A1 (es) | 2022-02-07 | 2024-05-08 | Genentech Inc | Proceso para la síntesis de compuestos de quinazolina |
| CN118742544A (zh) | 2022-02-07 | 2024-10-01 | 基因泰克公司 | 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式 |
-
2023
- 2023-04-04 PL PL23721096.8T patent/PL4504202T3/pl unknown
- 2023-04-04 CN CN202380032303.9A patent/CN119013026A/zh active Pending
- 2023-04-04 AU AU2023249068A patent/AU2023249068A1/en active Pending
- 2023-04-04 CA CA3255718A patent/CA3255718A1/en active Pending
- 2023-04-04 JP JP2024558455A patent/JP2025511352A/ja active Pending
- 2023-04-04 US US18/295,550 patent/US12383557B2/en active Active
- 2023-04-04 KR KR1020247032867A patent/KR20240167654A/ko active Pending
- 2023-04-04 ES ES23721096T patent/ES3067080T3/es active Active
- 2023-04-04 IL IL315250A patent/IL315250A/en unknown
- 2023-04-04 WO PCT/US2023/017455 patent/WO2023196329A1/en not_active Ceased
- 2023-04-04 EP EP23721096.8A patent/EP4504202B1/en active Active
- 2023-04-06 TW TW112112927A patent/TW202345846A/zh unknown
-
2024
- 2024-10-03 MX MX2024012230A patent/MX2024012230A/es unknown
-
2025
- 2025-07-14 US US19/268,721 patent/US20260053802A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US12383557B2 (en) | 2025-08-12 |
| EP4504202A1 (en) | 2025-02-12 |
| US20230321102A1 (en) | 2023-10-12 |
| IL315250A (en) | 2024-10-01 |
| CN119013026A (zh) | 2024-11-22 |
| KR20240167654A (ko) | 2024-11-27 |
| AU2023249068A1 (en) | 2024-09-05 |
| PL4504202T3 (pl) | 2026-05-04 |
| ES3067080T3 (en) | 2026-05-19 |
| TW202345846A (zh) | 2023-12-01 |
| CA3255718A1 (en) | 2023-10-12 |
| JP2025511352A (ja) | 2025-04-15 |
| US20260053802A1 (en) | 2026-02-26 |
| EP4504202B1 (en) | 2026-02-04 |
| WO2023196329A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019384119A8 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| CO2026004964A2 (es) | Moduladores de kras | |
| MX2021002804A (es) | Terapias de combinacion. | |
| CL2024003191A1 (es) | Compuestos de modulación de kras g12d | |
| CL2024003040A1 (es) | Tratamientos del cáncer con inhibidores de prmt5 cooperativos con mta | |
| CO2023006705A2 (es) | Inhibidores de gcn2 y perk quinasas y métodos de uso de los mismos | |
| CL2020002405A1 (es) | Inhibidores de kras g12c y métodos para su uso (divisional de la solicitud no. 201903394) | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| CO2024003949A2 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CL2021002176A1 (es) | Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos (divisional de la solicitud n° 202002040) | |
| CL2022001794A1 (es) | Terapia combinada que comprende inhibidores de a2a/a2b y pd-1/pd-l1. | |
| CL2021003170A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| PY2261702A (es) | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus | |
| MX2020013163A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| AU2019310335A8 (en) | Methods of treating cancer with PI3K inhibitor, GDC-0077 | |
| MX2023012744A (es) | Inhibidores de pcna e inhibidores de egfr para el tratamiento del cancer. | |
| BR112022025911A2 (pt) | Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante | |
| MX2022007623A (es) | Combinaciones. | |
| UY40457A (es) | Inhibidores de tead y métodos de uso de los mismos | |
| NO20051170L (no) | Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier | |
| CR20220071A (es) | Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| WO2022261467A9 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy |